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Abstract	
A	 prospective	 national	 cohort	 study	 was	 undertaken	 to	 collect	 data	 on	 all	 cases	 of	
paediatric	 (<18yrs	 of	 age)	 AKI	 identified	 by	 an	 e-alert,	 using	 the	 Welsh	 National	
electronic	 AKI	 reporting	 system.	 We	 describe	 the	 utility	 and	 limitation	 of	 using	 this	
creatinine	based	data	set,	to	characterise	paediatric	AKI.			
There	were	a	total	of	1,343	incident	episodes.		34.5%	of	episodes	occurred	in	neonates	
of	which	83.8%	were	AKI	stage	1.		Neonatal	30-day	mortality	was	4.1%	with	73.3%	of	
this	being	accounted	for	by	patients	treated	in	ICU.			
In	the	non-neonatal	group	76.1%	was	AKI	stage	1.	Hospital	acquired	AKI	accounted	for	
40.1%	of	AKI	episodes.	 	Community	acquired	AKI	represented	29.4%	of	which	33.9%	
were	 admitted	 to	 hospital.	 	 30.5%	 of	 cases	 were	 unclassified.	 Non-neonatal	 30-day	
mortality	was	1.2%,	with	50.0%	of	this	accounted	for	by	patients	treated	in	ICU.		Non-
recovery	of	renal	 function	at	30-days	occurred	 in	28%	and	was	significantly	higher	 in	
patients		not	admitted	to	hospital	(45%	vs.	20%).			
The	 reported	 incidence	 of	 AKI	 in	 children	 is	 far	 greater	 than	 previously	 reported	 in	
studies	reliant	on	clinical	identification	of	adult	AKI	or	hospital	coding	data.	 	Mortality	
was	highest	in	neonates	and	driven	by	those	in	ICU.		Non-recovery	of	renal	function	and	
persistent	 renal	 impairment	 was	 more	 common	 in	 non-neonates	 and	 was	 especially	
high	in	CA-AKI	not	hospitalised.			
	
	 	
Introduction	
Acute	Kidney	Injury	(AKI)	in	children	is	associated	with	longer	hospital	stay	1,	higher	in-
patient	 mortality	 2,	 and	 a	 higher	 incidence	 of	 long	 term	 renal	 abnormalities	 3.	 	 	 In	
contrast	 to	 adult	 AKI	 epidemiology,	much	 less	 data	 is	 available	 describing	 paediatric	
AKI,	with	few	studies	reporting	on	the	population	based	incidence	and	outcome	of	AKI	
in	paediatrics.		
	
Based	on	a	presumption	that	early	identification	may	help	raise	standards	of	care	and	
improve	patient	outcomes,	an	automated	real	time	e-alert	system	for	AKI	based	on	the	
KDIGO	 criteria	 has	 been	 established	 and	 implemented	 nationally	 across	 the	 National	
Health	Service	in	Wales.	Alerts	are	transmitted	as	text	attached	to	the	creatinine	result	
report.	 Creatinine	 values	 generating	 alerts	 are	 also	 highlighted	 red	 on	 the	 results	
reporting	 system	 to	 enhance	 their	 visibility	 to	 the	 requesting	 clinician.	 Using	 a	
centralised	 system	 of	 data	 collection,	we	 have	 previously	 reported	 the	 incidence	 and	
outcome	of	adult	AKI	in	which	the	diagnosis	of	AKI	was	based	on	an	electronic	alert	4.		
The	current	study	uses	the	national	data	set	to	describe	the	incidence	and	outcome	of	
AKI	in	the	paediatric	population	when	AKI	is	 identified	by	an	automated	biochemistry	
based	electronic	AKI	alert.		Our	aim	was	to	determine	the	utility	and	limitation	of	using	
this	 creatinine	 based	 AKI	 data	 set	 in	 paediatrics.	 	 In	 this	 manuscript	 we	 have	 also	
compared	 the	 performance	 of	 two	 proposed	 different	 AKI	 definitional	 interpretation	
methods	 to	 the	 use	 of	 the	 patients	 own	 previous	 results	 as	 used	 in	 the	 e-ALERT	
algorithm.		
	
	
Results	
There	 were	 2,087	 e-alerts	 (Table	 1),	 representing	 1,343	 incident	 AKI-alerts,	 and	 an	
incidence	rate	of	1.37	cases	per	1,000	person-years	for	those	under	the	age	of	18	years.		
Overall	30-	and	90-day	mortality	was	2.1%	and	2.9%	respectively.			Of	all	incident	AKI-
alert	episodes	59.9%	of	alerts	occurred	in	non-neonates	and	40.1%	in	neonates.	
	
Non-Neonate	paediatric	AKI	
The	mean	age	of	AKI-alert	 	patients	was	7.5	±6.1	years	and	AKI	was	more	common	in	
boys	 (52%).	 Electronic	 alerts	 classified	 the	majority	 of	 cases	 as	 AKI	 stage	 1	 (76.1%),	
with	15%	presenting	as	AKI	stage	2	and	only	8.9%	as	AKI	stage	3.		Overall	8.1%	of	the	
patients’	renal	function	deteriorated	to	a	higher	AKI	stage.		The	largest	number	of	alerts	
was	generated	by	Rule	3	followed	by	Rule	2.		
	
Hospital	acquired	(HA)-AKI	accounted	for	40.1%	of	AKI	episodes.		Community	acquired	
AKI	 represented	 29.4%	 of	 all	 incident	 episodes,	 in	 which	 33.9%	 resulted	 in	 hospital	
admission	within	7	days	of	the	incident	alert.	 	For	30%	of	all	alerts	generated	from	an	
inpatient	 setting	 the	 lack	 of	 information	 regarding	 the	 source	 of	 the	 baseline	 serum	
creatinine	 from	which	 the	 alert	was	 triggered	 led	 to	 classifying	 these	 as	AKI	 from	an	
undermined	clinical	setting	(i.e.	neither	hospital	or	community	acquired).	12.6%	of	all	
AKI	 episodes	 were	 admitted	 to	 the	 Intensive	 care	 unit	 within	 7	 days	 of	 the	 incident	
alert.			
Comparisons	to	different	baseline	definitions:	
The	definitional	 interpretation	of	AKI	varies	with	 the	 choice	of	different	baseline	SCr.		
For	paediatric	patients,	particularly	those	with	no	historical	biochemical	data,	using	an	
eGFR	of	120ml/min/1.73m2	to	define	‘normal’	baseline	and	back	calculating	a	baseline	
SCr	 or	 the	 use	 of	 normative	 values	 have	 been	 proposed	 5.	 	 	 We	 compared	 the	
performance	of	these	two	methods	to	derive	a	baseline	SCr	to	the	patient’s	own	actual	
baseline	identified	by	the	National	algorithm.	 	Using	the	former	method	resulted	in	an	
estimated	 baseline	 SCr	 which	 was	 significantly	 lower	 than	 that	 obtained	 from	 the	
patient’s	 own	 previous	 results	 (0.40	 ±0.13mg/dL	 vs.	 0.52	 ±0.73mg/dL,	 p<0.001).		
Average	 baseline	 SCr	 value	 using	 normative	 midpoint	 values	 more	 closely	
approximated	 the	 patient’s	 own	 baseline-based	 historical	 biochemistry	 (0.63	
±0.23mg/dL	 vs.	 0.52	 ±0.73mg/dL,	 p<0.001).	 	 	 Bland-Altman	 analysis	 (Figure	 1)	
demonstrates	 significant	 non-agreement	 between	 algorithm	 and	 estimated	 baseline	
creatinine	 values	 regardless	 of	 the	method	 that	 is	 used	 for	 baseline	 estimation,	 with	
progressive	 less	 agreement	 as	 estimated	 baseline	 values	 rise.	 	 Equal	 unit	 bias	 and	
therefore	 an	 equal	 degree	 of	 agreement	 between	 algorithm-eCCl120	 methods	 of	
determining	 baseline	 creatinine	 values,	 and	 algorithm-normative	 midpoint	 methods.		
The	 positive	 percentage	 bias	 confirms	 that	 compared	 to	 the	 patient’s	 actual	 baseline	
(generated	 by	 the	 algorithm)	 the	 generation	 of	 a	 baseline	 by	 back-calculating	 from	
eCCl120,	is	likely	to	underestimate	SCr	leading	to	over-diagnosis	of	AKI.				
	
Outcomes:	
30-	and	90-day	mortality	for	the	non-neonatal	cohort	was	1.2%	and	1.8%	respectively,	
with	 50.0%	 of	 the	 30-day	 mortality	 accounted	 for	 by	 patients	 treated	 in	 ICU,	 and	
mortality	 limited	 only	 to	 HA-AKI	 alerts.	 	 By	 linear	 regression	 mortality	 was	 not	
associated	with	AKI	severity	either	AKI	stage	at	presentation	nor	peak	AKI	stage.		Non-
recovery	of	renal	function	at	30-	and	90-days	occurred	in	27.5%	and	25.8%	of	patients	
respectively.	 	 For	patients	who	had	 recovery	of	 renal	 function	 following	 the	alert,	 the	
mean	time	to	recovery	was	4.2±6.6	days.		Persistent	renal	impairment	as	judged	by	an	
eGFR	<50%	of	normal	was	14.3%	at	30-days	and	13.4%	at	90-days.	
	
It	 of	 note	 that	 the	 majority	 of	 alerts	 in	 the	 non-neonate	 group	 are	 derived	 from	 a	
baseline	generated	by	the	median	creatinine	for	the	preceding	365	days.		This	may	be	of	
concern	particularly	in	a	paediatric	cohort	in	which	growth	and	changes	in	muscle	mass	
influence	creatinine	values.		In	this	cohort	however	the	renal	outcome,	for	patients	with	
an	 alert	 generated	 by	 rule	 3	 (≥50%	 creatinine	 increase	 from	median	 value	 of	 results	
within	the	last	8-365	days)	as	determined	by	non-recovery	of	renal	function	at	90	days	
was	 comparable	 to	 the	 outcome	 following	 rule	 2	 alerts	 (≥50%	 increase	 in	 creatinine	
within	 previous	 7	 days),	 suggesting	 that	 alerts	 generated	 by	 both	 rules	 have	 similar	
clinical	significance	(non-recovery	26.1%	rule	3	vs.	29%	rule	2;	p=0.43).			
	
The	 relationship	between	admission	 to	hospital	 and	 renal	outcome	 for	all	 community	
acquired	 AKI	 alert	 groups	 is	 shown	 in	 table	 2.	 There	 was	 no	 difference	 in	 mortality	
between	 hospitalised	 and	 non-hospitalization.	 	 In	 contrast	 hospitalization	 was	
associated	with	better	outcome	in	terms	of	recovery	from	the	acute	episode	at	both	30	
and	90-days	and	a	lower	proportion	of	patients	developing	an	eGFR	<60ml/min/1.73m2	
for	 the	 first	 time	 (this	 did	 not	 reach	 statistical	 significance	 at	 90	 days	 due	 to	 small	
patient	 numbers).	 	 There	 was	 a	 positive	 relationship	 between	 the	 time	 to	 repeat	
measurement	 of	 renal	 function	 and	 hospitalisation	 with	 a	 significantly	 longer	 mean	
time	 to	 first	 repeat	 for	 patients	 not	 hospitalised	 (10.1±8.8	 vs.	 1.1±1.4days,	 p<0.001)	
which	suggests	 that	 lack	of	admission	may	be	associated	with	a	 lack	of	 recognition	of	
the	 significance	 of	 an	AKI	 e-alert.	 By	 linear	 regression	better	 acute	 outcome	 adjusted	
was	also	associated	with	hospitalization	(HR	2.01;	95%	CI	1.29-3.23;	p=0.003)	but	was	
not	associated	with	severity	of	AKI	as	measured	by	either	AKI	stage	at	presentation	or	
peak	AKI	stage.				
	
	
	
Neonates	
For	AKI	 in	 neonates	 the	majority	 of	 episodes	were	 classified	 as	AKI	 stage	 1	 (83.8%),	
with	13%	presenting	as	AKI	stage	2	and	only	3.2%	as	AKI	stage	3.		Overall	14.7%	of	the	
patients’	 renal	 function	deteriorated	 to	a	higher	AKI	stage	(Table	3).	 	For	 the	neonate	
group	the	vast	majority	(88.9%)	of	AKI	was	diagnosed	using	a	baseline	patient	derived	
SCr	generated	within	7	days	of	the	acute	event	(rule	2).			
	
Comparisons	to	different	baseline	definitions:	
Using	an	eGFR	of	120ml/min/1.73m2	to	define	‘normal’	baseline	and	back	calculating	a	
baseline	SCr	resulted	 in	an	estimated	baseline	SCr	which	was	significantly	 lower	 than	
that	obtained	from	the	patients	previous	results	which	would	 lead	to	“over-diagnosis”	
of	AKI	 (0.17	±0.00mg/dL	vs.	0.43	±0.24mg/dL,	p<0.001).	 In	contrast	average	baseline	
SCr	 value	 using	 normative	 midpoint	 values	 more	 closely	 approximated	 the	 patient’s	
own	 baseline-based	 upon	 historical	 biochemistry	 (0.38	 ±	 0.00mg/dL	 vs.	 	 0.43	
±0.24mg/dL,	 p<0.001).	 	 As	 in	 the	 non-neonate	 group	 there	 was	 significant	 non-
agreement	 between	 algorithm	 and	 estimated	 baseline	 creatinine	 values	 regardless	 of	
the	 method	 that	 is	 used	 for	 baseline	 estimation,	 with	 progressive	 less	 agreement	 as	
estimated	baseline	values	rise.		In	this	group	however	Bland-Altman	analysis	(Figure	2)	
and	 difference	 in	 unit	 bias,	 demonstrates	 stronger	 agreement	 between	 algorithm-
normative	midpoint	 methods	 compared	 to	 the	 agreement	 between	 algorithm-eCCl120	
methods.			
	
Within	 the	 neonatal	 cohort	 additional	 concerns	 have	 been	 raised	 that	 errors	 in	
laboratory	 measurement	 in	 patients	 with	 very	 low	 SCr	 values	 may	 lead	 to	 over	
“diagnosis”	 of	 AKI.	 	 To	 overcome	 this,	 a	modification	 of	 the	 KDIGO	 serum	 creatinine	
based	criteria	with	the	modification	that	a	minimum	SCr	of	greater	than	0.5mg/dL	has	
previously	been	applied	6	to	qualify	as	AKI,	based	on	the	normal	SCr	in	newborns	on	day	
7	7,	8.	 	 	69.6%	of	all	neonatal	AKI	 flagged	by	an	electronic	alert	occurred	 in	patients	 in	
which	the	baseline	creatinine	was	<0.5mg/dL.		Of	these	52.4%	had	a	rise	in	creatinine	to	
>0.5mg/dL	and	47.6%	had	a	rise	in	creatinine	to	≤0.5mg/dL.	 	This	latter	group,	which	
represents	 33.1%	 of	 all	 neonatal	 AKI,	 could	 be	 excluded	 if	 the	 aforementioned	
modification	was	applied.			
	
Outcomes	
30-	 and	 90-day	 mortality	 for	 the	 whole	 neonatal	 cohort	 was	 4.1%	 and	 5.5%	
respectively.		46.6%	of	the	neonatal	cohort	were	treated	in	ICU	and	73.3%	of	the	30-day	
neonatal	mortality	was	accounted	 for	by	patients	 treated	 in	 ICU,	and	89.5%	(17	of	19	
deaths)	 in	patients	with	HA-AKI	alerts.	 	As	with	 the	non-neonate	group	mortality	was	
not	however	associated	with	AKI	severity	either	AKI	stage	at	presentation	nor	peak	AKI	
stage.		For	the	whole	neonatal	cohort	persistent	renal	impairment	as	judged	by	an	eGFR	
<50%	 of	 normal	 was	 4%	 at	 30-days	 and	 1.6%	 at	 90-days.	 For	 patients	 who	 had	
recovery	 of	 renal	 function	 following	 the	 alert,	 the	 mean	 time	 to	 recovery	 was	
4.3±5.8days.	 	 As	with	 the	no-neonatal	 cohort	 renal	 outcome	by	 linear	 regression	was	
not	 associated	 with	 severity	 of	 renal	 injury	 as	 measured	 by	 either	 AKI	 stage	 at	
presentation	or	peak	AKI	stage.					
	
For	those	patients	triggering	an	AKI	e-alert	with	a	baseline	creatinine	<0.5mg/dL	and	a	
rise	 to	 ≤0.5mg/dL	 there	 were	 no	 patient	 deaths	 and	 no	 patients	 at	 90-days	 had	
persistent	 renal	 impairment	 as	 judged	 by	 an	 eGFR	 <50%.	 	 In	 contrast	 for	 those	
triggering	an	AKI	e-alert	with	a	baseline	creatinine	<0.5mg/dL	and	a	rise	to	>0.5mg/dL	
the	mortality	at	30-days	(4.4%)	and	90-days	(5.2%),	and	persistent	renal	impairment	at	
both	 30-days	 (3.6%)	 and	 90-days	 (1.9%)	 were	 both	 no	 different	 to	 the	 outcome	
measures	for	the	whole	neonatal	group.				
	
Discussion	
The	reported	incidence	of	AKI	varies	depending	on	its	definition,	the	clinical	setting	in	
which	 it	 is	 detected	 and	 the	 population	 studied.	 Definitional	 differences	make	 direct	
comparison	of	epidemiological	data	challenging,	and	potentially	hinder	the	ability	of	the	
renal	 community	 to	 improve	 outcomes,	 highlighting	 the	 need	 to	 adopt	 a	 single	 and	
universal	 definition.	 	 This	 principle	 of	 a	 single	 diagnostic	 criteria,	 underpins	 the	
adoption	of	a	centralised	laboratory	based	definition	of	AKI	in	Wales.	 	Many	published	
studies	 describing	 AKI	 have	 focused	 upon	 either	 HA-AKI	 or	 CA-AKI	 requiring	
hospitalisation	thus	failing	to	collect	complete	data	on	CA-AKI.	In	this	study,	in	the	non-
neonatal	group,	CA-AKI	represents	almost	a	third	of	all	AKI	cases	of	which	a	significant	
proportion	were	not	admitted	to	hospital.	 	These	would	therefore	not	be	incorporated	
into	any	analysis	of	CA-AKI	based	upon	admission	to	hospital.		
	
Our	reported	incidence	is	significantly	higher	than	previously	reported	in	children.		To	
date,	two	national	data	sets	have	been	published	describing	the	epidemiology	of	AKI	in	
children.		A	retrospective	data	set	generated	from	ICD-10	codes	in	Norway,	reported	an	
incidence	of	AKI	 in	children	under	the	age	of	16yrs	of	3.3	cases	per	100,000	children,	
and	also	suggested	an	increasing	incidence	of	AKI	with	time	9.		Possible	explanations	to	
the	 discrepancy	 in	 incidence	may	 therefore	 be	 that	 there	 has	 been	 a	 true	 increase	 in	
incidence	since	 the	 termination	of	 this	 study,	 the	younger	age	cut	off	 for	definition	of	
‘paediatric’,	 and	 the	 limitations	of	 reliance	on	 identification	by	 coding.	 	 In	 the	 largest	
cohort	 of	 paediatric	AKI	 cases	 reported	 to	date,	 Sutherland	 and	 colleagues	 report	 3.9	
cases	 of	 AKI	 per	 1,000	 hospital	 admissions,	 although	 the	 reliance	 on	 ICD-9	 coding	 is	
likely	 to	 lead	 to	 an	 underestimation	 of	 AKI	 diagnosis	 2.	 	 In	 addition	 AKI	 in	 the	
community	was	not	collected.	 	Both	of	these	studies,	as	with	our	data,	demonstrated	a	
male	 predominance.	 	 Whilst	 a	 male	 predominance	 in	 adult	 cases	 of	 AKI	 has	 been	
previously	 documented	 this	 has	 not	 been	 widely	 reported	 in	 paediatric	 populations.		
Both	studies	also	demonstrate	a	bimodal	age	distribution	with	AKI	occurring	in	the	very	
young	and	in	the	15-18	years	age	group.		Our	data	is	also	consistent	with	these	findings	
demonstrating	a	high	incidence	of	AKI	in	neonates.			
	
The	 high	 incidence	 of	 AKI	 amongst	 the	 neonatal	 population	 in	 our	 study	 should	 be	
qualified	by	our	reliance	of	a	creatinine	based	definition.		These	youngest	children	have	
lower	 serum	 creatinine	 values	 and	 therefore	 small	 changes,	 even	with	 the	 use	 of	 age	
adjusted	 normal	 ranges,	 result	 in	 the	 trigger	 of	 an	 AKI	 alert.	 One	 suggestion	 is	 the	
requirement	of	a	rise	in	SCr	to	>0.5mg/dL	for	patients	with	a	baseline	SCr	<0.5mg/dL	to	
generate	an	AKI	alert,	to	prevent	over-diagnosis	of	AKI	in	the	neonatal	cohort	based	on	
the	 inherent	 error	 of	 the	 lab	 measurement.	 	 	 Our	 data	 demonstrates	 that	 a	 third	 of	
neonates,	fulfilling	the	diagnosis	of	AKI	by	change	in	SCr,	belong	to	this	category	where	
the	rise	 in	SCr	 is	<0.5mg/dL.	 	The	 lack	of	association	with	either	mortality	or	residual	
renal	 impairment	would	support	suppression	of	 the	alert	 for	 this	specific	group.	 	This	
represents	 a	 pragmatic	 approach	 to	 avoid	 alert	 fatigue	 by	 reducing	 the	 rate	 of	 false	
positivity	 of	 the	 alerting	 system	 although	 clearly	 a	 change	 in	 creatinine	 within	 this	
range	 may	 represent	 a	 true	 episode	 of	 AKI	 in	 some	 cases	 emphasising	 the	 need	 for	
clinical	scrutiny	rather	ran	total	reliance	on	an	alerting	system	designed	to	highlight	the	
most	“at	risk”	patient	groups.				The	relevance	of	an	electronic	alert	in	this	cohort	is	also	
limited	 by	 the	 lack	 of	 information	 such	 as	 gestational	 age	 and	 the	 relevance	 of	 small	
changes	 in	 creatinine	 in	 low	 birth	 weight/premature	 infants,	 further	 supporting	
suppression	 of	 alerts	 in	 the	 context	 of	 “low	 creatinine”	 baseline.	 	 Creatinine	 based	
definitions	 of	 AKI	 in	 the	 neonate	 are	 also	 complicated	 by	 unique	 factors	 such	 as	 the	
presence	 of	 maternal	 creatinine,	 varying	 degrees	 of	 creatinine	 reabsorption	 in	 the	
proximal	 tubules	 and	 maturational	 differences	 especially	 in	 sick	 neonates	 with	
persistent	pulmonary	hypertension	and/or	hypoxic	ischaemic	encephalopathy	10.			
	
Mortality	 in	 our	 paediatric	 population	 was	 predominantly	 driven	 by	 neonates	 and	
consistent	 with	 previous	 publications,	 more	 specifically	 neonates	 in	 ICU.	 In	 the	 non-
neonatal	 group,	 although	 mortality	 was	 much	 lower,	 this	 was	 also	 driven	 to	 a	 large	
extent	by	those	admitted	to	ICU.		This	is	consistent	with	the	recently	published	AWARE	
study	 in	 which	 acute	 kidney	 injury	 in	 the	 context	 of	 ICU	 was	 associated	 with	 poor	
outcomes,	 including	 increased	 mortality	 11.	 	 Previous	 data	 in	 children	 suggest	 that	
outside	the	ICU	group	there	is	no	association	between	AKI	and	mortality	which	is	likely	
to	reflect	the	nature	of	a	paediatric	population	in	which	death	is	infrequent	2,	12.		It	is	of	
note	that	our	reported	mortality	associated	with	AKI	is	significantly	less	than	previously	
reported	studies,	which	have	reported	mortality	rates	as	high	as	15%	2.		This	likely	to	be	
explained	 by	 our	 definitional	 diagnosis	 based	 on	 biochemical	 parameters	 rather	 than	
coding	data,	resulting	in	higher	AKI	capture	rates.	In	addition	our	data	demonstrate	that	
mortality	 	was	not	associated	with	the	degree	of	renal	injury,	at	 least	as	assessed	by	a	
change	in	serum	creatinine.		Mortality	is	therefore	more		likely		to	reflect	the	severity	of	
the	underlying	disease	leading	to	impaired	renal	function.		 
	
Although	mortality	following	AKI	in	the	non-neonatal	group	is	significantly	better	than	
in	 the	 neonatal	 group,	 the	 converse	 is	 true	 for	 the	 development	 of	 persistent	 renal	
impairment.	 	 In	 this	group	 there	was	a	 significant	proportion	 in	whom	renal	 function	
did	not	 return	 to	normal	which	 translated	 into	 roughly	15%	developing	an	eGFR	 less	
than	 50%	 of	 the	 age	 adjusted	 normal	 value	 at	 90-days.	 These	 data	 are	 of	 particular	
importance	as	it	is	increasingly	recognised	that	this	lack	of	recovery	may	translate	into		
longer-term	ongoing	progressive	renal	 injury	3.	 	At	 least	 in	adults,	recent	data	suggest	
that	90	day	SCr	is	a	legitimate	surrogate	end	point	for	ESRD	after	AKI	13.			
	
A	 challenge	 for	 clinicians	 reporting	AKI	 relates	 to	 the	ascertainment	of	baseline	 renal	
function.	 	 This	 is	 of	 particular	 importance	 in	 paediatrics	 in	which	 previous	 results	 of	
blood	tests	are	often	unavailable,	and	is	particularly	challenging	in	neonates.		It	is	clear	
however	that	AKI	definition	variation	causes	significant	heterogeneity	 in	 terms	of	AKI	
diagnosis	and	reporting.	Recent	work	by	Zappitelli	and	colleagues	reported	differences	
in	 incidence	 from	4.6%	to	43.1%	 in	non-critically	 ill	hospitalised	children	5.	 	Accurate	
identification	of	AKI	is	an	important	goal	as	AKI	when	associated	with	relatively	small	
increases	 in	 SCr	 are	 associated	with	 	 adverse	 clinical	 outcomes	 in	 children	 14.	 	As	 the	
electronic	alerting	system	is	based	on	direct	comparison	of	SCr	with	the	patient’s	own	
previous	 results	 we	 used	 this	 to	 compare	 with	 two	 previously	 suggested	 models	 to	
provide	 an	 estimate	 of	 baseline	 renal	 function	 in	 the	 absence	 of	 historic	 comparison.		
The	argument	 for	back	 calculation	based	on	an	eGFR	of	120ml/min/1.73m2	 has	been	
presented	previously	5,	15.	 	 	Our	results	however	clearly	demonstrate,	that	compared	to	
the	patients’	own	results,	this	approach	would	lead	to	significant	over	reporting	of	AKI	
in	 children.	 	 In	 contrast	 the	 use	 of	 the	 normative	 midpoint	 value	 provides	 a	 more	
accurate	 reflection	 of	 the	 true	 patient	 baseline,	 and	may	 therefore	 be	 the	 preferable	
approach	 for	 generating	 baseline	 estimations	 of	 renal	 function	 in	 the	 absence	 of	
previous	measurements	of	renal	function.		
	
Although	this	study	is	to	our	knowledge	the	first	national	study	using	an	e-alert	based	
system	to	characterise	the	magnitude	and	impact	of	AKI	in	children,	its	findings	need	to	
be	 qualified	 by	 its	 limitations.	 Our	 data	 reports	 the	 incidence	 of	 AKI	 in	 which	 the	
diagnosis	 is	 a	 creatinine	 based	 definition	 in	 which	 the	 baseline	 creatinine	 may	 be	
generated	based	on	a	blood	sample	taken	in	the	preceding	365	days.		As	such,	this	does	
not	meet	 the	 strict	 agreed	AKI	definition	of	 “abrupt	deterioration”,	 and	does	not	 take	
into	account	a	“urine	output”	based	AKI	diagnosis.	 	 In	part,	discrepancies	 in	 incidence	
between	our	data	and	previously	reported	incidence	may	therefore	be	definitional.		The	
number	of	blood	tests	undertaken	in	children	is	much	lower	than	in	adults	with	recent	
data	 suggesting	 that	 less	 than	 20%	 of	 inpatients	 will	 have	 repeated	 estimations	 of	
serum	creatinine	during	an	in-patient	admission	16.		Therefore,	our	definition	addresses	
the	 lack	 of	 creatinine	monitoring	 in	 non-critically	 ill	 young	people.	 	 The	 study	 is	 also	
limited	 in	 that	 any	 patient	 presenting	 with	 AKI	 but	 with	 no	 measurement	 of	 renal	
function	in	the	previous	365	days	will	not	be	included	in	our	analysis,	which	therefore	
may	underestimate	the	true	incidence	of	AKI.		This	approach	however	does	preclude	the	
inclusion	of	the	first	presentation	of	AKI	in	a	patient	with	no	previous	blood	test	on	the	
system.	 	 These	 patients	 are	 highlighted	 as	 “high	 creatinine”	 which	 needs	 further	
investigations,	but	are	not	 included	 in	 this	data	 set.	 	Using	an	 IT	based	approach	also	
precludes	inclusion	of	clinical	information,	such	as	patient	co-morbidity,	patient	volume	
status	 and	 the	 detail	 of	 the	 cause	 of	 AKI.	 	 Despite	 these	 limitations	 our	 study	 uses	 a	
creatinine	based	electronic	AKI	alert	 to	provide	 the	 first	 large	scale	description	of	 the	
incidence	 and	 outcome	 of	 paediatric	 AKI.	 	 In	 addition,	 it	 provides	 a	measure	 against	
which	 alternative	 models	 for	 predicting	 baseline	 renal	 function	 in	 children	 can	 be	
measured.			
	
Methods	
Setting	
Data	was	collected	from	the	Laboratory	Information	Management	System	(LIMS)	on	all	
patients	 aged	 <18yrs	 of	 age,	 that	 triggered	 an	 AKI	 electronic	 alert	 (e-alert)	 in	Wales.		
The	study	was	approved	under	the	terms	of	Service	Evaluation	Project	Registration.			
	
Development	of	Electronic	Reporting	System	
The	 previously	 described	 (and	 validated)	 Welsh	 electronic	 AKI	 reporting	 system	 4,	
utilizes	an	algorithm	based	upon	changes	 in	serum	creatinine	 level	and	does	not	 take	
into	 account	 urine	 output	 (Supplementary	 figure	 1).	 	 Creatinine	 is	 measured	 using	
kinetic	Jaffe	methodology	on	various	analytical	platforms	across	Wales.		All	methods	are	
standardised	 by	 using	 ID/MS	 calibrated	 reference	 material.	 LIMS	 (Intersystems	
TrakCare	Lab)	generates	an	electronic	AKI	alert	by	automatically	comparing	measured	
creatinine	values	on	an	 individual	patient	against	previous	 results	on	 the	 system.	 	An	
alert	is	therefore	only	generated	for	patients	who	have	previous	results	recorded.		For	
patients	with	a	raised	creatinine	(above	 the	 laboratory	normal	values)	no	AKI	alert	 is	
generated	although	the	abnormal	result	 is	highlighted	to	 the	requesting	clinician	with	
the	 following	 text	 “Raised	creatinine:	if	not	known	CKD	suggest	repeat	to	rule	out	Acute	
Kidney	Injury”.			
Three	“rules”	are	applied	to	generate	alerts	differing	in	the	time	period	from	which	the	
baseline	creatinine	is	obtained	(Table	1).	Rule	2	alerts	represent	a	≥50%	increase	in	SCr	
within	 the	previous	7	days,	a	rule	3	alert	represents	a	≥50%	increase	 in	SCr	 from	the	
median	 of	 results	 from	 the	 previous	 8	 to	 365	 days,	 and	 rule	 1	 alerts	 represent	 a	
>26µmol/L	 increase	 in	SCr	within	 the	previous	48	hours	and	are	 issued	only	 if	 rule	1	
and	 rule	 2	 are	 not	 satisfied.	 Repeat	 alerts	 are	 suppressed	 if	 the	 creatinine	 value	
generated	 is	 not	 greater	 than	 the	 previous	 by	 2CV%	 of	 the	 between	 batch	 variation	
method	 where	 CV	 is	 the	 coefficient	 of	 variation	 (standard	 deviation	 expressed	 as	 a	
percentage	of	the	mean).	At	present	the	All	Wales	agreement	is	that	2CV	is	6%	.	
Data	Collection	
Prospective	data	was	collected	 for	all	 cases	of	paediatric	 (<18yrs	of	age)	AKI	 from	1st	
November	2013	to	30th	April	2016.		Details	of	cohort	creation	are	shown	in	figure	3.		All	
alerts	occurring	within	30	days	of	the	first	episode	were	defined	as	the	same	episode	of	
AKI.			
	
Incidence	 rate	 was	 calculated	 using	 Mid-2015	 Office	 for	 National	 Statistics	 (ONS)	
Population	 Estimates	 17.	 	 All	 patients	 for	 which	 the	 first	 alert	 was	 issued	 during	 a	
hospital	admission	having	had	a	blood	test	which	generated	a	normal	serum	creatinine	
(SCr)	value	taken	in	a	hospital	setting	within	the	preceding	seven	days	were	defined	as	
Hospital	acquired	(HA)-AKI.	Patients	alerting	in	a	non-inpatient	setting	were	classified	
as	 community	 acquired	 (CA)-AKI.	 	 Patients	 alerting	 in	 an	 in-patient	 setting	 with	 no	
results	for	the	previous	7	days	were	classified	as	‘Undetermined	in	hospital	alerts’	as	it	
was	not	possible	to	confidently	classify	these	as	either	CA-	or	HA-AKI.	Hospitalization	of	
CA-AKI	was	defined	as	a	measurement	of	 renal	 function	 in	a	hospital	 setting	within	7	
days	 of	 the	 alert.	 	 To	 be	 classified	 as	 AKI	 treated	 in	 the	 Intensive	 Care	 Unit	 (ICU)	
patients	either	alerted	AKI	in	ICU,	or	had	a	measurement	of	renal	function	in	ICU	within	
7	days	of	the	AKI	e-alert.	Progression	of	AKI	was	defined	as	a	peak	AKI	stage	higher	than	
the	incident	e-alert	or	for	stage	3	alerts	an	increase	≥50%	from	the	SCr	generating	the	
alert.	
	
Mortality	data	was	collected	 from	the	Welsh	Demographic	Service	 (WDS)	 18.	 	Patients	
were	 censored	 at	 27	months	 for	 survival	 analysis.	 30-day	 and	 90-day	 renal	 outcome	
analysis	required	patients	 to	have	 follow	up	data	available	and	 included	only	patients	
surviving	at	these	time	points.		
Recovery	was	defined	as	achievement	of	a	serum	creatinine	(SCr)	value	closest	to	and	
within	the	follow	up	time	period	which	was	not	consistent	with	the	definition	of	AKI	in	
comparison	to	baseline	SCr	values.		
Persistent	renal	impairment	was	defined	as	an	eGFR	<50%	of	the	age	adjusted	normal	
value	based	on	the	serum	creatinine	value	closest	to	and	within	either	30	or	90	days	of	
in	the	incident	alert.	We	calculated	eGFR	using	the	Schwartz	method	8,	19	and	used	age-
related	 50th	 percentile	 heights	 20.	 Pre-existing	 CKD	 was	 defined	 as	 a	 baseline	 eGFR	
<50%	of	normal.		
Alternative	 definitions	 of	 baseline	 SCr	 5	 were	 derived	 by	 using	 either	 estimated	
creatinine	 clearance	 criteria	 (eCCl120)	 assuming	 an	 eCCl=120ml/min/1.73m2	 to	 back	
calculate	a	baseline	SCr,	or	by	using	midpoint	normative	creatinine	values	for	age	and	
gender	 21	 as	 are	 currently	 the	 reference	 ranges	 (suppl	 table	 1)	 used	 in	Wales	 (Wales	
LIMS	 Harmonisation).	 	 These	 values	 were	 then	 compared	 to	 the	 national	 algorithm	
derived	baseline	creatinine	value.				
	
Statistical	analysis		
Statistical	analysis	was	carried	out	using	SPSS	software,	version	20	(SPSS,	Inc.,	Chicago,	
IL).	Student’s	t	test	was	used	for	analysis	of	normally	distributed	data.	Categorical	data	
were	 compared	 using	 a	 Pearson	 chi-squared	 test.	 	 P	 values	 less	 than	 0.05	 were	
considered	statistically	significant.		
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Legends	
Figure	 1:	 Comparison	 of	 the	 Algorithm	 method	 of	 defining	 baseline	 Serum	
Creatinine	with	the	estimated	creatinine	clearance	criteria	(eCCl120)	method,	and	
the	method	of	using	midpoint	normative	values	(NormMid)	in	non-neonates.	
A:	 Bland-Altman	 plot	 of	 differences	 between	 the	 Algorithm	method	 and	 the	 eCCl120	
method	 vs.	 the	 mean	 of	 the	 two	 measurements,	 where	 differences	 are	 expressed	 as	
units	(mg/dL).	B:	Bland-Altman	plot	of	differences	between	the	Algorithm	method	and	
the	 NormMid	method	 vs.	 the	mean	 of	 the	 two	measurements,	 where	 differences	 are	
expressed	as	units	(mg/dL).	C:	Bland-Altman	plot	of	differences	between	the	Algorithm	
method	 and	 the	 eCCl120	 method	 vs.	 the	 mean	 of	 the	 two	 measurements,	 where	
differences	 are	 expressed	 as	 percentage	 (%).	 D:	 Bland-Altman	 plot	 of	 differences	
between	 the	 Algorithm	 method	 and	 the	 NormMid	 method	 vs.	 the	 mean	 of	 the	 two	
measurements,	where	differences	are	expressed	as	percentage	(%).		
The	bias	 is	 represented	by	 the	 gap	between	 the	 central	 dotted	 line,	 corresponding	 to	
zero	differences,	and	the	solid	parallel	line	to	the	X	axis	which	represents	the	mean.	The	
dotted	 lines	 represent	 the	 lower	 and	 upper	 limits	 of	 agreement,	 from	 -1.96SD	 and	
+1.96SD.	
	
Figure	 2:	 Comparison	 of	 the	 Algorithm	 method	 of	 defining	 baseline	 Serum	
Creatinine	with	the	estimated	creatinine	clearance	criteria	(eCCl120)	method,	and	
the	method	of	using	midpoint	normative	values	(NormMid)	in	neonates.	
A:	 Bland-Altman	 plot	 of	 differences	 between	 the	 Algorithm	method	 and	 the	 eCCl120	
method	 vs.	 the	 mean	 of	 the	 two	 measurements,	 where	 differences	 are	 expressed	 as	
units	(mg/dL).	B:	Bland-Altman	plot	of	differences	between	the	Algorithm	method	and	
the	 NormMid	method	 vs.	 the	mean	 of	 the	 two	measurements,	 where	 differences	 are	
expressed	as	units	(mg/dL).	C:	Bland-Altman	plot	of	differences	between	the	Algorithm	
method	 and	 the	 eCCl120	 method	 vs.	 the	 mean	 of	 the	 two	 measurements,	 where	
differences	 are	 expressed	 as	 percentage	 (%).	 D:	 Bland-Altman	 plot	 of	 differences	
between	 the	 Algorithm	 method	 and	 the	 NormMid	 method	 vs.	 the	 mean	 of	 the	 two	
measurements,	where	differences	are	expressed	as	percentage	(%).		
The	bias	 is	 represented	by	 the	 gap	between	 the	 central	 dotted	 line,	 corresponding	 to	
zero	differences,	and	the	solid	parallel	line	to	the	X	axis	which	represents	the	mean.	The	
dotted	 lines	 represent	 the	 lower	 and	 upper	 limits	 of	 agreement,	 from	 -1.96SD	 and	
+1.96SD.	
	
Figure	3:		Cohort	creation,	exclusion	and	inclusion	criteria.	
	
Supplementary	 Figure	 1:	 Algorithm	 for	 generating	 e-alerts	 for	 Acute	 Kidney	 Injury	
based	on	serum	creatinine	(SCr)	changes	with	time.		RV,	Reference	value,	defined	as	the	
SCr	value	with	which	 the	 index	SCr	value	 is	 compared;	D,	difference	between	current	
and	lowest	previous	result	within	48	hours;	RI,	Population	reference	interval.		
	
	
	
	
	 	
Table	1.	Characteristics	of	the	paediatric	cohort.		
Variable	 All	paediatrics	 Neonates	
Non-
neonates	
AKI	e-alerts,	n	 2,087	 837	 1,250	
Incident	episodes	(Incident	rate/1000)	 1,343	(1.37)	 468	 875	
Mean	age	±SD		 4.90	±6.04	yrs	 4.5	±6.3	days	 7.5	±6.13	yrs	
Neonate,	%	(n)	 34.8	(468)	 	 	
Male	%	(n)	 54.6	(730)	 60.2	(278)	 51.7	(452)	
Mean	bSCr	±SD	(mg/dL)	 0.49	±0.61	 0.43	±0.24	 0.52	±0.73	
Mean	bSCr	(eCCl120)	±SD	(mg/dL)		 0.32	±0.16	 0.17	±0.00	 0.40	±0.13	
Mean	baseline	SCr	(NormMid)	±SD	(mg/dL)	 0.54	±0.22	 0.38	±0.00	 0.63	±0.23	
Pre-existing	CKD,	%	(n)	 	 	 6.1	(53)	
Mean	alert	SCr	±SD	(mg/dL)	 0.90	±1.30	 0.73	±0.35	 0.99	±1.58	
Mean	peak	SCr	±SD	(mg/dL)	 0.99	±1.46	 0.80	±0.43	 1.09	±1.77	
AKI	Stage	of	alert,	%	(n)			Stage	1		 83.2	(1,117)	 83.8	(392)	 82.9	(725)	
																																											Stage	2		 11.6	(156)	 13.0	(61)	 10.9	(95)	
																																												Stage	3		 5.2	(70)	 3.2	(15)	 6.3	(55)	
Peak	AKI	Stage,	%	(n)								Stage	1	 74.1	(995)	 70.3	(329)	 76.1	(666)	
																																												Stage	2		 17.4	(234)	 22.0	(103)	 15.0	(131)	
																																												Stage	3		 8.5	(114)	 7.7	(36)	 8.9	(78)	
AKI	Rule,	%	(n)																				Rule	1		 4.7	(63)	 8.8	(41)	 2.5	(22)	
																																												Rule	2		 54.4	(731)	 88.9	(416)	 36.0	(315)	
																																												Rule	3		 40.9	(549)	 2.4	(11)	 61.5	(538)	
Progression	of	AKI,	%	(n)	 10.4	(140)	 14.7	(69)	 8.1	(71)	
Mean	time	to	peak	SCr	±SD	(d)	 6.31	±8.04	 4.29	±6.27	 8.20	±9.02	
HA-AKI,	%	(n)	
	
91.0	(426	 40.1	(351)	
CA-AKI,	%	(n)	
	
2.4	(11)	 29.4	(257)	
Undetermined	in	hospital	alert	,	%	(n)	
	
6.6	(31)	 30.5	(267)	
30	day	mortality,	%	(n)	 2.06	(25)	 4.14	(15)	 1.18	(10)	
90	day	mortality,	%	(n)	 2.89	(35)	 5.52	(20)	 1.77	(15)	
Non-recovery	at	30	days,	%	(n)	 	 	 28.2	(158)	
Non-recovery	at	90	days,	%	(n)	 	 	 26.7	(168)	
eGFR	<50%	of	normal	at	30	days,	%	(n)	 11.4	(107)	 6.9	(26)	 14.5	(81)	
eGFR	<50%	of	normal	at	90	days,	%	(n)	 9.3	(92)	 4.2	(15)	 12.2	(77)	
Data	on	patient	sex	were	missing	for	7	episodes	(6,	Neonate;	1,	Non-neonate)	and	excluded	from	analysis	of	
the	 sex	 variable.	Data	on	baseline	 eGFR	was	missing	 for	16	 episodes	 (11,	Neonates;	 5,	Non-neonates)	and	
excluded	 from	 analysis	 of	 the	 Pre-existing	 CKD	 variable.	 Mortality	 data	 was	 available	 for	 1211	 episodes	
(362,	 Neonates;	 849,	 Non-neonates).	 30	 day	 outcome	 SCr	 data	 was	 available	 for	 939	 episodes	 (378,	
Neonates;	561,	Non-neonates)	for	which	mean	time	to	the	result	used	to	determine	30	day	outcome	±SD	was	
15.4	±10.9	days	(18.3	±10.1	days,	Neonates;	13.4	±11.0	days,	Non-neonates)	and	within	which	mean	time	to	
recovery	±SD	was	4.3	±6.2	days	(4.3	±5.8	days,	Neonates;	4.2	±6.5	days,	Non-neonates).	30	day	outcome	eGFR	
data	 was	 available	 for	 936	 episodes	 (376,	 Neonates;	 560,	 Non-neonates).	 90	 day	 outcome	 SCr	 data	 was	
available	 for	 986	 episodes	 (356,	Neonates;	 630,	Non-neonates)	 for	which	mean	 time	 to	 the	 result	 used	 to	
determine	 90	 day	 outcome	 ±SD	 was	 36.9	 ±30.9	 days	 (35.7	 ±29.5	 days,	 Neonates;	 37.7	 ±31.6	 days,	 Non-
neonates)	and	within	which	mean	time	to	recovery	±SD	was	8.1	±15.1	days	 (6.5	±11.9	days,	Neonates;	9.1	
±16.8	days,	Non-neonates).	90	day	outcome	eGFR	data	was	available	for	984	episodes	(355,	Neonates;	629,	
Non-neonates).CKD,	Chronic	Kidney	disease;	bSCr,	Baseline	 serum	creatinine;	 eCCl120,	 estimated	 creatinine	
clearance;	 NormMid,	 Normative	 midpoint;	 HA-AKI,	 Hospital	 acquired-AKI;	 CA-AKI,	 Community	 acquired-
AKI.	
Table	2.	Comparison	of	hospitalised	and	non-hospitalised	Community	acquired	
paediatric	patients.	
	
Hospitalized	 Non-hospitalized	 P	value	
Number	of	episodes	 91	 177	 	
Mean	time	to	repeat	±SD	(days)	 1.1	±1.4	 10.1	±8.8	 P<0.001	
Progression	of	AKI,	%	(n)	 11.0	(10)	 2.8	(5)	 P=0.006	
Mean	time	to	peak	SCr	±SD	(days)	 5.9	±8.0	 19.7	±7.4	 P<0.001	
30	day	mortality,	%	(n)	 1.1	(1)	 0.6	(1)	 P=n/s	
Non-recovery	at	30	days	 20.0	(18)	 45.1	(23)	 P=0.002	
eGFR	<50%	of	normal	at	30	days	 12.2	(11)	 25.5	(13)	 0=0.04	
90	day	mortality,	%	(n)	 1.1	(1)	 0.6	(1)	 P=n/s	
Non-recovery	at	90	days	 16.4	(9)	 54.5	(18)	 P<0.001	
eGFR	<50%	of	normal	at	90	days	 9.1	(5)	 21.2	(7)	 P=n/s	
Mortality	data	was	available	for	254	episodes	(90,	Hospitalized;	164,	Non-hospitalized).	30	day	outcome	
SCr	 and	 eGFR	 data	 was	 available	 for	 141	 episodes	 (90,	 Hospitalized;	 51,	 Non-hospitalized).	 90	 day	
outcome	SCr	and	eGFR	data	was	available	for	88	episodes	(55,	Hospitalized;	33,	Non-hospitalized).		
	
	
	
Table	3.	Characteristics	of	the	neonate	cohort	with	a	baseline	SCr	<0.5mg/dL	
Variable	
bSCr	<0.5mg/dL	
and	rose	to	
>0.5mg/dL	
bSCr	<0.5mg/dL	
and	rose	to	
≤0.5mg/dL	
Incident	episodes,	n	 171	 155	
Mean	age	±SD	(days)	 3.46	±0.01	 8.96	±0.02	
Sex,	%	(n)	 	
	Male	 59.4	(101)	 62.6	(97)	
Female	 40.6	(69)	 37.4	(58)	
Mean	bSCr	±SD	(mg/dL)	 0.38	±0.09	 0.23	±0.04	
Mean	alert	SCr	±SD	(mg/dL)	 0.70	±0.13	 0.40	±0.06	
Mean	peak	SCr	±SD	(mg/dL)	 0.78	±0.25	 0.44	±0.12	
Progression	of	AKI,	%	(n)	 14.6	(25)	 13.5	(21)	
Stage	1	that	progress	 17.5	(22)	 14.0	(18)	
Stage	1	that	progress	to	stage	3	 6.3	(8)	 1.6	(2)	
Stage	2	that	progress	 9.4	(3)	 11.5	(3)	
Mean	time	to	peak	SCr	±SD	(days)	 4.16	±5.95	 6.27	±8.18	
30	day	mortality,	%	(n)	 4.41	(6)	 0	
90	day	mortality,	%	(n)	 5.15	(15)	 0.78	(1)	
eGFR	<50%	of	normal	at	30	days,	%	(n)	 5.3	(8)	 0	
eGFR	<50%	of	normal	at	90	days,	%	(n)	 2.8	(4)	 0	
Data	on	patient	 sex	was	missing	 for	1	episode	and	excluded	 from	analysis	of	 the	 sex	variable	 for	 the	bSCr	
<0.5mg/dL	 and	 rose	 to	 >0.5mg/dL	 group.	Mortality	 data	 was	 available	 for	 264	 episodes	 (136,	 Rose	 to	
>0.5mg/dL;	 128,	Rose	 to	 ≤0.5mg/dL).	 30	day	outcome	SCr	and	 eGFR	data	was	available	 for	 253	 episodes	
(151,	Rose	to	>0.5mg/dL;	102,	Rose	to	≤0.5mg/dL).	90	day	outcome	SCr	and	eGFR	data	was	available	for	241	
episodes	(141,	Rose	to	>0.5mg/dL;	100,	Rose	to	≤0.5mg/dL).		bSCr,	Baseline	serum	creatinine;	CKD,	Chronic	
Kidney	disease;	 SCr,	 Serum	creatinine;	 eCCl120,	 estimated	 creatinine	 clearance;	HA-AKI,	Hospital	 acquired-
AKI;	CA-AKI,	Community	acquired-AKI.	
	
Supplementary	Table	1.	Normative	Serum	Creatinine	values	for	age	and	gender.	
Source:	Wales	LIMS	(Laboratory	Information	Management	System)	Harmonisation	
Group	
Age	(yrs)	 Gender	 Lower	(mg/dL)	 Upper	(mg/dL)	 Midpoint	(mg/dL)	
0-1	 M/F	 0.17	 0.42	 0.38	
1-4	 M/F	 0.19	 0.49	 0.44	
5-9		 M/F	 0.26	 0.61	 0.57	
10-14	 M/F	 0.35	 0.86	 0.78	
15-17	 M		 0.44	 1.10	 0.99	
15-17	 F	 0.44	 1.04	 0.96	
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